◀ Back to NPPA

NPPA — PGF

Text-mined interactions from Literome

Jiang et al., Sheng Li Xue Bao 2005 (Hypertrophy, Right Ventricular) : In vitro experiments showed that 0.1 micromol/L PGF ( 2alpha ) significantly increased the cardiomyocyte diameter and protein content, and promoted ANP and CaN mRNA expressions, which was blocked by cyclosporin A, a CaN inhibitor
Jiang et al., Acta Pharmacol Sin 2007 (Cardiomegaly) : PGF2alpha ( 100 nmol/L ) significantly increased the cardiomyocyte diameter, protein content and [Ca2+ ] i, and promoted ANP , CaN mRNA, and CaN/NFAT3/GATA4 protein expressions, which were inhibited by either Rb1 in a concentration dependent manner ( 50, 100, and 200 microg/mL ) or L-arginine ( 1 mmol/L )
Bai et al., Peptides 2009 (Hypertension, Renal) : PGF2alpha and PGD2 caused dose dependent increases in ANP release and intra-atrial pressure ... The potency for the stimulation of ANP secretion by PGF2alpha was higher than that by PGD2 ... The increases in intra-atrial pressure and ANP secretion induced by PGF2alpha and PGD2 were significantly attenuated by the pretreatment with an inhibitor of PGF2alpha receptor ... By the pretreatment with an inhibitor for phospholipase C (PLC), inositol 3-phosphate ( IP3 ) receptor, protein kinase C ( PKC ), or myosin light chain kinase (MLCK), PGF2alpha mediated increase in ANP secretion and positive inotropy were attenuated ... In hypertrophied rat atria, PGF2alpha induced positive inotropy and ANP secretion were markedly attenuated whereas COX-2 inhibitor stimulated ANP secretion ... These results suggest that PGF2alpha increased the ANP secretion and positive inotropy through PLC-IP3-PKC-MLCK pathway, and the modulation of ANP secretion by COX-2 inhibitor and PGF2alpha may partly relate to the development of renal hypertension